July 28, 2014 5:52 AM ET


Company Overview of Geneva Pharmaceuticals Technology Corporation

Company Overview

Geneva Pharmaceuticals Technology Corporation researches and develops generic pharmaceuticals. The company was formerly known as Invamed, Inc. and changed its name to Geneva Pharmaceuticals Technology Corporation in 1999. As a result of the acquisition of Invamed, Inc. by Sandoz, Inc., Invamed, Inc.'s name was changed. The company is based in Dayton, New Jersey. As of 12/09/1999, Geneva Pharmaceuticals Technology Corporation is a subsidiary of Sandoz, Inc.

2400 US Highway 130

Dayton, NJ 08810

United States





Key Executives for Geneva Pharmaceuticals Technology Corporation

Geneva Pharmaceuticals Technology Corporation does not have any Key Executives recorded.

Similar Private Companies By Industry

Company Name Region
Solaray, Inc. United States
En Garde Health Products, Inc. United States
Channel Therapeutics Inc. United States
Azaya Therapeutics Incorporated United States
ProMedTek, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Geneva Pharmaceuticals Technology Corporation, please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.